Free Trial

Sanford C. Bernstein's Rating of Gilead Sciences on 11/2/2026

On November 2, 2026, Sanford C. Bernstein updated its outlook on Gilead Sciences (NASDAQ:GILD) with the action "Reiterated Rating", keeping a "Outperform" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Sanford C. Bernstein

DateCompanyAction
11/2/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Reiterated Rating
11/2/2026
Qualcomm Incorporated stock logo
QCOM
Qualcomm
Lower Price Target
11/2/2026
nVent Electric PLC stock logo
NVT
nVent Electric
Reiterated Rating
11/2/2026
Amphenol Corporation stock logo
APH
Amphenol
Reiterated Rating
11/2/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Boost Price Target
11/2/2026
Incyte Corporation stock logo
INCY
Incyte
Boost Price Target
More Ratings From Sanford C. Bernstein